140 related articles for article (PubMed ID: 36938826)
1. A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor-positive disease.
Storr SJ; Hoskin V; Aiyappa-Maudsley R; Ghaffari A; Varma S; Green A; Rakha E; Ellis IO; Greer PA; Martin SG
Cancer Med; 2023 May; 12(9):10908-10916. PubMed ID: 36938826
[TBL] [Abstract][Full Text] [Related]
2. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.
Andersson G; Wennersten C; Gaber A; Boman K; Nodin B; Uhlén M; Segersten U; Malmström PU; Jirström K
BMC Urol; 2014 May; 14():36. PubMed ID: 24885195
[TBL] [Abstract][Full Text] [Related]
4. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
6. High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series.
Kunc M; Pęksa R; Cserni G; Iżycka-Świeszewska E; Łacko A; Radecka B; Braun M; Pikiel J; Litwiniuk M; Pogoda K; Szwajkosz A; Biernat W; Senkus E
Pathology; 2022 Apr; 54(3):269-278. PubMed ID: 35074178
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
10. High expression of EZR (ezrin) gene is correlated with the poor overall survival of breast cancer patients.
Zhang R; Zhang S; Xing R; Zhang Q
Thorac Cancer; 2019 Oct; 10(10):1953-1961. PubMed ID: 31452341
[TBL] [Abstract][Full Text] [Related]
11. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
12. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
13. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
14. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
15. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
16. Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.
Wennersten C; Andersson G; Boman K; Nodin B; Gaber A; Jirström K
Diagn Pathol; 2014 Oct; 9():189. PubMed ID: 25278252
[TBL] [Abstract][Full Text] [Related]
17. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
[TBL] [Abstract][Full Text] [Related]
18. High nuclear MSK1 is associated with longer survival in breast cancer patients.
Pu X; Storr SJ; Ahmad NS; Rakha EA; Green AR; Ellis IO; Martin SG
J Cancer Res Clin Oncol; 2018 Mar; 144(3):509-517. PubMed ID: 29327245
[TBL] [Abstract][Full Text] [Related]
19. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
[TBL] [Abstract][Full Text] [Related]
20. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.
Alqaisi A; Chen L; Romond E; Chambers M; Stevens M; Pasley G; Awasthi M; Massarweh S
Breast Cancer Res Treat; 2014 Nov; 148(2):437-44. PubMed ID: 25257728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
